UPADACITINIB
upadacitinib 15 mg modified release tablet, 28
UPADACITINIB (13768P)
13768P
Manner of administration:Oral
Restriction
Indication: Severe Crohn disease
Treatment phase: Continuing (maintenance) treatment
Restriction
Indication: Severe Crohn disease
Treatment phase: Balance of supply for the Continuing (maintenance) treatment phase
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 5 | DPMQ: $1,212.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Rinvoq | |||||